Hand osteoarthritis: A fresh look

Pascal Richette; Augustin Latourte

doi:10.1016/j.jbspin.2023.105652

Hand osteoarthritis: A fresh look

Joint Bone Spine. 2023 Oct 4;91(4):105652. doi: 10.1016/j.jbspin.2023.105652. Online ahead of print.

Authors

Pascal Richette¹, Augustin Latourte²

Affiliations

¹ Service de rhumatologie, hôpital Lariboisière, Paris, France. Electronic address: pascal.richette@aphp.fr.
² Service de rhumatologie, hôpital Lariboisière, Paris, France.

PMID: 37797830
DOI: 10.1016/j.jbspin.2023.105652

Abstract

Hand osteoarthritis (OA) has been the subject of numerous publications in recent years, particularly in the fields of imaging and therapeutics. The imaging studies revealed a good correlation between the presence of synovitis and/or subchondral edema and arthritic joint pain. Several randomized controlled trials (RCTs) have assessed the efficacy of biologics and conventional DMARDs in patients with symptomatic hand OA. No less than six RCTs have evaluated the symptomatic and, in some cases, structural efficacy of anti-IL-1, anti-TNF or anti-IL-6 drugs. Overall, the results of these trials were disappointing - none of them demonstrated superiority over placebo. There were also two negative trials with hydroxychloroquine. In the end, the only trial that was positive evaluated 10mg oral prednisone versus placebo for 6 weeks in patients with flares of hand OA and synovitis visible on ultrasound. While that trial confirms the role of inflammation in hand OA, it should obviously not encourage the long-term use of corticosteroids as a symptomatic treatment.

Keywords: Hand; Imaging; Osteoarthritis; Treatment.